The most widely used high-dose chemotherapy (HDC) before autologous stem cell transplant (ASCT) is BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) [1, 2] , which is considered the gold standard both in United States and Europe [3, 4] . However, carmustine has been often substituted by other molecules due to its difficult supplying and high costs [3, 5] . In Italy, the most frequently used alternative regimen is FEAM (fotemustine, etoposide, cytarabine, melphalan), in which carmustine is replaced by fotemustine, a third-generation chloroethyl-nitrosourea with ability to cross the blood-brain barrier and a more favorable pulmonary toxicity profile, however not available in all European countries [6] . Even though only two phase-2 studies have been until now published [7, 8] , the Italian Regulatory Agency for medical products granted reimbursement of fotemustine by the National Health Service as component of FEAM regimen. Based on these considerations, we aimed to investigate in a retrospective study the comparison between BEAM and FEAM regimen in terms of efficacy and safety in lymphoma patients undergoing ASCT.
From January 2007 to January 2017, 362 consecutive lymphoma patients undergoing ASCT after BEAM (n = 200) and FEAM (n = 162) were analyzed by reviewing clinical records in two centers of Rome (Sapienza University n = 218 and Regina Elena National Cancer Institute n = 144), both accredited according to JACIE standards. Selection for HDC was only based on carmustine availability. In particular, due to difficult supplying of carmustine, FEAM regimen was planned in all patients from September 2011 to August 2015 in Sapienza University and Regina Elena Institute, respectively. All patients had signed a specific informed consent for HDC and for data analysis.
FEAM was administered according to the original protocol [7] : fotemustine 150 mg/m 2 on days −7 and −6, etoposide 100 mg/m 2 twice daily and cytarabine 200 mg/m 2 twice daily on days −5, −4, −3, and −2, and melphalan 140 mg/m 2 on day −1. BEAM consisted of carmustine 300 mg/m 2 on day −6, etoposide and cytarabine 100 mg/m 2 twice daily on days −5, −4, −3, and −2, and melphalan 140 mg/m 2 on day −1 [1, 2] . Peripheral blood stem cells were infused on day 0. All patients underwent an uniform supporting, anti-infectious and transfusion policy. Treatment response assessment was based on international revised response criteria for malignant lymphoma [9, 10] . Progression-free survival (PFS), overall survival (OS), transplant-related mortality (TRM), and engraftment were defined as usually. Safety was evaluated by recording acute adverse events (AEs) and graduated according to common terminology criteria of the National Cancer Institute.
Primary end-point was the treatment response rate assessed at day −100 after ASCT. Secondary end-points were: conversion rate into complete remission (CR) from a worst disease status (partial remission [PR], stable disease [SD] , and progressive disease [PD] ) assessed at day +100 after ASCT, PFS and OS, cumulative incidence of relapse, engraftment, AEs, days of hospitalization, and TRM.
Data were analyzed by Statistical Package of Social Sciences software (version 20.0, Chicago, USA). Comparison between the two patient cohorts was performed by using χ 2 test (Fisher or Pearson) and Mann-Whitney test for categorical and quantitative variables, respectively. PFS and OS were estimated with Kaplan-Meier method and compared with two-side log-rank test. Two-sided P values below 0.05 were considered statistically significant. Due to difference in follow-up duration of the two cohorts of patients, post-transplant day-100 response assessment was used as primary end-point and a logistic regression model was implemented in order to better investigate associations among factors and end-point. A stepwise method was adopted to perform a forward selection based on Wald statistic.
BEAM and FEAM patient groups were well balanced for all features except for diagnosis, because of an imbalance in the proportion of diffuse large B-cell lymphoma (DLBCL) (43% in BEAM vs 27% in FEAM) and mantle cell lymphoma (MCL) (8% in BEAM vs 20% in FEAM). Moreover, there was a significant difference in the median follow-up (77 months for BEAM vs 25 for FEAM; P < 0.0001), due to the fact that FEAM was more recently introduced (Table 1) .
We observed a significantly higher probability of being in a CR status at post-transplant day-100 assessment in the BEAM group compared with FEAM (87% vs 74.7%; P = 0.01) ( Table 1) . This difference was also appreciable considering the two most represented diagnosis subgroups apart, Hodgkin's lymphoma (HL) and DLBCL (87.3% vs 75.6%; P = 0.11 and 82.8% vs 63.6%; P = 0.03, respectively) ( Table 1) . At multivariate analysis, the HDC regimen was the only independent factor able to significantly affect the probability of achieving a posttransplant CR (BEAM vs FEAM odds ratio: 2.26, 95% CI: 1.28-3.99; P = 0.005), together with pre-transplant disease status (CR vs no CR odds ratio: 4.72, 95% CI: 2.66-8.35; P < 0.0001). The increase of CR rate between pre-transplant and post-transplant assessment was slightly higher in patients of BEAM group compared with FEAM for overall population (+20.5% vs +13%; P = 0.09), significantly higher for HL patients (+30.9% vs +8.9%; P = 0.007), but not for DLBCL patients (+17.3% vs +13.6%; P = 0.45).
As for the conversion rate into CR from a worst disease status, in the BEAM group we found a significantly higher rate of patients able to improve their pretransplant disease status: out of 67 patients in PR-SD/ PD, 50 upgraded their disease status toward a CR after BEAM, compared with 35 out of 62 patients after FEAM (75% vs 56%; P = 0.03), with the largest gain observed in DLBCL patients (80% after BEAM vs 45% after FEAM; P = 0.007). As for time-dependent variables, we did not observe a significant difference between the two cohorts in PFS (2 yrs-PFS BEAM: 76% vs FEAM: 74%; P = 0.211), cumulative incidence of relapse (2-yrscumulative incidence of relapse BEAM: 12% vs FEAM: 14%; P = 0.235), and OS (2 years OS BEAM: 87% vs FEAM: 84%; P = 0.578), as shown in Fig. 1 . Similar results were also obtained by single institution analysis (data not shown). Median time to Absolute Neutrophils Count (ANC) and Platelets (PLT) recovery were similar between the two groups (BEAM: 10 and 13 days vs FEAM: 10 and 14 days, respectively). In FEAM group, we observed a significantly higher incidence of grade 3-4 oral mucositis (FEAM: 51.9% vs BEAM: 30.5%; P < 0.0001), clinically or microbiologically documented infectious complications (FEAM: 45.7% vs BEAM: 36%; P = 0.05), and intravenous antibiotics need (FEAM: 80.2% vs BEAM: 63.5%; P = 0.01). Other toxicities (hepatic, renal, and pulmonary) were very rare and similarly distributed. Transfusion need, hospitalization days, and TRM were similar. Finally, we did not observe significant differences in terms of typology of microbiologically documented infections between the two cohorts.
BEAM is considered the gold standard HDC for lymphoma patients undergoing ASCT. Efficacy and safety profile of this regimen are well known, being used since 1990s. The data from our study are absolutely similar to those reported in literature as for post-transplant day-100 assessment, PFS, OS, and safety [3] , indicating the reliability of our BEAM comparison arm. Despite a longlasting knowledge of efficacy and safety accumulated over two decades, in the last years we have been assisting to numerous attempts to substitute carmustine by developing alternative regimens with bendamustine [11] , thiotepa [12] , oral lomustine [13] , or busulfan-based regimens [14] , in absence of randomized trials. In Italy, the most frequently used alternative regimen is FEAM. In two published single-arm studies, carmustine was replaced by fotemustine [7, 8] , but studies comparing BEAM and FEAM in lymphoma patients are lacking. At the best of our knowledge, only one multicenter study has been recently published in abstract form [15] . The study included 766 patients undergoing ASCT in 16 Italian centers, but data were quite heterogeneous and several patients received a reduced dose of chemotherapy, particularly in the FEAM group. The results were similar to ours, having however FEAM regimen a worse 1-year PFS (80% vs 87%; P = 0.02). The authors reported a significantly higher rate of mucositis, diarrhea, vomiting, and Gram-negative infections in FEAM group. In our study, the multivariate logistic regression model clearly showed that HDC regimen was able to independently affect the probability to be in CR at post-transplant assessment together with disease status at transplant. Moreover, BEAM regimen was more effective to convert PR/SD-PD into CR, particularly in DLBCL patients. However, we did not observe differences between the groups in terms of 2 years PFS and OS, perhaps because of the shorter follow-up of patients of FEAM group. BEAM regimen seems to be better tolerated because of significantly lower rates of mucositis and infectious complications. The main weakness of our study is the non-randomized design. However, the involvement of two JACIE accredited Institutions sharing the same procedures for ASCT, and the substantial reproducibility of results by each participating Institution, both suggest the lack of "center effect", so to guarantee a good data reliability. Secondly, as the choice of HDC was only due to carmustine availability, it is likely that a significant selection bias has been avoided. Thirdly, although there was a significant diagnosis imbalance between the cohorts, both univariate and multivariate analysis have convincingly excluded that the diagnosis has had an impact on the primary end-point. In conclusion, BEAM regimen seems to be better tolerated than FEAM. Although PFS and OS in our study are similar to date, BEAM should remain the regimen of choice in lymphoma patients undergoing ASCT on the basis of both a higher probability of post-transplant CR and much longer followup. Prospective randomized trials are warrant to confirm these results. 
